245 related articles for article (PubMed ID: 15716344)
1. A splice variant of the Wilms' tumour suppressor Wt1 is required for normal development of the olfactory system.
Wagner N; Wagner KD; Hammes A; Kirschner KM; Vidal VP; Schedl A; Scholz H
Development; 2005 Mar; 132(6):1327-36. PubMed ID: 15716344
[TBL] [Abstract][Full Text] [Related]
2. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways.
Wang ZY; Qiu QQ; Huang J; Gurrieri M; Deuel TF
Oncogene; 1995 Feb; 10(3):415-22. PubMed ID: 7845666
[TBL] [Abstract][Full Text] [Related]
3. The Wilms' tumor gene Wt1 is required for normal development of the retina.
Wagner KD; Wagner N; Vidal VP; Schley G; Wilhelm D; Schedl A; Englert C; Scholz H
EMBO J; 2002 Mar; 21(6):1398-405. PubMed ID: 11889045
[TBL] [Abstract][Full Text] [Related]
4. The Wilms tumour suppressor protein WT1 (+KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain.
Morrison AA; Venables JP; Dellaire G; Ladomery MR
Biochem Cell Biol; 2006 Oct; 84(5):789-98. PubMed ID: 17167543
[TBL] [Abstract][Full Text] [Related]
5. Wilms tumor and the WT1 gene.
Lee SB; Haber DA
Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
[TBL] [Abstract][Full Text] [Related]
6. Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice.
Smith SI; Down M; Boyd AW; Li CL
Cancer Res; 2000 Feb; 60(4):808-14. PubMed ID: 10706085
[TBL] [Abstract][Full Text] [Related]
7. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.
Han Y; San-Marina S; Yang L; Khoury H; Minden MD
Breast Cancer Res; 2007; 9(4):R43. PubMed ID: 17634147
[TBL] [Abstract][Full Text] [Related]
8. A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers.
Little MH; Holmes G; Pell L; Caricasole A; Duarte A; Law M; Ward A; Wainwright B
Oncogene; 1996 Oct; 13(7):1461-9. PubMed ID: 8875984
[TBL] [Abstract][Full Text] [Related]
9. Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells.
Burwell EA; McCarty GP; Simpson LA; Thompson KA; Loeb DM
Oncogene; 2007 May; 26(23):3423-30. PubMed ID: 17160023
[TBL] [Abstract][Full Text] [Related]
10. A cell-autonomous role for WT1 in regulating Sry in vivo.
Bradford ST; Wilhelm D; Bandiera R; Vidal V; Schedl A; Koopman P
Hum Mol Genet; 2009 Sep; 18(18):3429-38. PubMed ID: 19549635
[TBL] [Abstract][Full Text] [Related]
11. Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro.
Jomgeow T; Oji Y; Tsuji N; Ikeda Y; Ito K; Tsuda A; Nakazawa T; Tatsumi N; Sakaguchi N; Takashima S; Shirakata T; Nishida S; Hosen N; Kawakami M; Tsuboi A; Oka Y; Itoh K; Sugiyama H
Cancer Sci; 2006 Apr; 97(4):259-70. PubMed ID: 16630117
[TBL] [Abstract][Full Text] [Related]
12. WT1 interacts with the splicing protein RBM4 and regulates its ability to modulate alternative splicing in vivo.
Markus MA; Heinrich B; Raitskin O; Adams DJ; Mangs H; Goy C; Ladomery M; Sperling R; Stamm S; Morris BJ
Exp Cell Res; 2006 Oct; 312(17):3379-88. PubMed ID: 16934801
[TBL] [Abstract][Full Text] [Related]
13. The ratio of +/-KTS splice variants of the Wilms' tumour suppressor protein WT1 mRNA is determined by an intronic enhancer.
Yang C; Romaniuk PJ
Biochem Cell Biol; 2008 Aug; 86(4):312-21. PubMed ID: 18756326
[TBL] [Abstract][Full Text] [Related]
14. The Wilms' tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells.
Kirschner KM; Hagen P; Hussels CS; Ballmaier M; Scholz H; Dame C
FASEB J; 2008 Aug; 22(8):2690-701. PubMed ID: 18424770
[TBL] [Abstract][Full Text] [Related]
15. Wilms' tumor 1-KTS isoforms induce p53-independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor.
Menke AL; Shvarts A; Riteco N; van Ham RC; van der Eb AJ; Jochemsen AG
Cancer Res; 1997 Apr; 57(7):1353-63. PubMed ID: 9102224
[TBL] [Abstract][Full Text] [Related]
16. Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway.
Ito K; Oji Y; Tatsumi N; Shimizu S; Kanai Y; Nakazawa T; Asada M; Jomgeow T; Aoyagi S; Nakano Y; Tamaki H; Sakaguchi N; Shirakata T; Nishida S; Kawakami M; Tsuboi A; Oka Y; Tsujimoto Y; Sugiyama H
Oncogene; 2006 Jul; 25(30):4217-29. PubMed ID: 16518414
[TBL] [Abstract][Full Text] [Related]
17. Expression in Xenopus oocytes shows that WT1 binds transcripts in vivo, with a central role for zinc finger one.
Ladomery M; Sommerville J; Woolner S; Slight J; Hastie N
J Cell Sci; 2003 Apr; 116(Pt 8):1539-49. PubMed ID: 12640038
[TBL] [Abstract][Full Text] [Related]
18. The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1.
Wagner N; Wagner KD; Xing Y; Scholz H; Schedl A
J Am Soc Nephrol; 2004 Dec; 15(12):3044-51. PubMed ID: 15579507
[TBL] [Abstract][Full Text] [Related]
19. New insights into DNA-binding behavior of Wilms tumor protein (WT1)--a dual study.
Nurmemmedov E; Yengo RK; Uysal H; Karlsson R; Thunnissen MM
Biophys Chem; 2009 Dec; 145(2-3):116-25. PubMed ID: 19853363
[TBL] [Abstract][Full Text] [Related]
20. Anlaysis of complementary expression profiles following WT1 induction versus repression reveals the cholesterol/fatty acid synthetic pathways as a possible major target of WT1.
Rae FK; Martinez G; Gillinder KR; Smith A; Shooter G; Forrest AR; Grimmond SM; Little MH
Oncogene; 2004 Apr; 23(17):3067-79. PubMed ID: 15021918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
